RNA interference inhibits DUX4-induced muscle toxicity in vivo: Implications for a targeted FSHD therapy

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1417-1423

  Wallace, Lindsay M ^a,b   Liu, Jian ^b   Domire, Jacqueline S ^a,b   Garwick Coppens, Sara E ^b   Guckes, Susan M ^b   Mendell, Jerry R ^a,b,c   Flanigan, Kevin M ^a,b,c   Harper, Scott Q ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; PARVOVIRUS VECTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DUX4 GENE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE; GENE SILENCING; GENE TARGETING; GRIP STRENGTH; IN VIVO STUDY; MOUSE; MUSCLE DISEASE; MUSCLE REGENERATION; MUSCLE TOXICITY; MUSCLE WEAKNESS; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

EID: 84863450530     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.68     Document Type: Conference Paper

References (35)

1. Flanigan, KM (2004). Facioscapulohumeral muscular dystrophy and scapuloperoneal disorders. In: Engel, AG and Franzini-Armstrong, C (eds.). Myology, 3rd edn., vol. 2. McGraw-Hill Medical Publishing Division: New York. pp. 1123-1133.
2. Prevalence of Rare Diseases: Bibliographic Data .http://www.orpha.net/ orphacom/cahiers/docs/GB/Prevalence-of-rare-diseases-by-alphabetical-list.pdf
3. Tawil, R (2008). Facioscapulohumeral muscular dystrophy. Neurotherapeutics 5: 601-606.
4. Bosnakovski, D, Daughters, RS, Xu, Z, Slack, JM and Kyba, M (2009). Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. PLoS ONE 4: e7003.
5. Dixit, M, Ansseau, E, Tassin, A, Winokur, S, Shi, R, Qian, H et al. (2007). DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci USA 104: 18157-18162. (Pubitemid 350210837)
6. Gabellini, D, Green, MR and Tupler, R (2002). Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 110: 339-348.
7. Gabrïs, J, Beckers, MC, Ding, H, De Vriese, A, Plaisance, S, van der Maarel, SM et al. (1999). Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 236: 25-32. (Pubitemid 29347656)
8. Kowaljow, V, Marcowycz, A, Ansseau, E, Conde, CB, Sauvage, S, Mattitti, C et al. (2007). The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord 17: 611-623. (Pubitemid 47030917)
9. Lemmers, RJ, van der Vliet, PJ, Klooster, R, Sacconi, S, Cama, P, Dauwerse, JG et al. (2010). A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329: 1650-1653.
10. Lemmers, RJ, Wohlgemuth, M, van der Gaag, KJ, van der Vliet, PJ, van Teijlingen, CM, de Knijff, P et al. (2007). Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am J Hum Genet 81: 884-894. (Pubitemid 47580243)
11. Snider, L, Geng, LN, Lemmers, RJ, Kyba, M, Ware, CB, Nelson, AM et al. (2010). Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet 6: e1001181.
12. van Overveld, PG, Lemmers, RJ, Sandkuijl, LA, Enthoven, L, Winokur, ST, Bakels, F et al. (2003). Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet 35: 315-317. (Pubitemid 37486913)
13. Wallace, LM, Garwick, SE, Mei, W, Belayew, A, Coppee, F, Ladner, KJ et al. (2011). DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Ann Neurol 69: 540-552.
14. Wijmenga, C, Hewitt, JE, Sandkuijl, LA, Clark, LN, Wright, TJ, Dauwerse, HG et al. (1992). Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 2: 26-30.
15. Padberg, G, Eriksson, AW, Volkers, WS, Bernini, L, Van Loghem, E, Meera Khan, P et al. (1984). Linkage studies in autosomal dominant facioscapulohumeral muscular dystrophy. J Neurol Sci 65: 261-268. (Pubitemid 14074736)
16. Hewitt, JE, Lyle, R, Clark, LN, Valleley, EM, Wright, TJ, Wijmenga, C et al. (1994). Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum Mol Genet 3: 1287-1295. (Pubitemid 24255461)
17. Bosnakovski, D, Xu, Z, Gang, EJ, Galindo, CL, Liu, M, Simsek, T et al. (2008). An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J 27: 2766-2779.
18. Harper, SQ, Staber, PD, He, X, Eliason, SL, Martins, IH, Mao, Q et al. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102: 5820-5825. (Pubitemid 40559643)
19. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873. (Pubitemid 351758464)
20. Wallace, LM, Garwick, SE, and Harper, SQ (2010). RNAi therapy for dominant muscular dystrophies and other myopathies. In: Duan, D (ed.). Muscle Gene Therapy. Springer: New York. pp. 99-115.
21. Wallace, LM, Garwick-Coppens, SE, Tupler, R and Harper, SQ (2011). RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1). Mol Ther 19: 2048-2054.
22. Bortolanza, S, Nonis, A, Sanvito, F, Maciotta, S, Sitia, G, Wei, J et al. (2011). AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Mol Ther 19: 2055-2064.
23. Boudreau, RL, Garwick-Coppens, SE, Liu, J, Wallace, LM and Harper, SQ (2011). Rapid cloning and validation of microRNA shuttle vectors: a practical guide. In: Harper, SQ (ed.). RNA Interference Techniques, vol. 1. Humana Press: New York. pp. 19-37.[Walz W (Series Editor): Neuromethods].
24. Laoudj-Chenivesse, D, Carnac, G, Bisbal, C, Hugon, G, Bouillot, S, Desnuelle, C et al. (2005). Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle. J Mol Med 83: 216-224. (Pubitemid 40487410)
25. Sandri, M, El Meslemani, AH, Sandri, C, Schjerling, P, Vissing, K, Andersen, JL et al. (2001). Caspase 3 expression correlates with skeletal muscle apoptosis in Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatmenti J Neuropathol Exp Neurol 60: 302-312. (Pubitemid 32209649)
26. Kunkel, LM, Hejtmancik, JF, Caskey, CT, Speer, A, Monaco, AP, Middlesworth, W et al. (1986). Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 322: 73-77. (Pubitemid 16061511)
27. Sicinski, P, Geng, Y, Ryder-Cook, AS, Barnard, EA, Darlison, MG and Barnard, PJ (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578-1580. (Pubitemid 19189735)
28. Ryder-Cook, AS, Sicinski, P, Thomas, K, Davies, KE, Worton, RG, Barnard, EA et al. (1988). Localization of the mdx mutation within the mouse dystrophin gene. EMBO J 7: 3017-3021.
29. Goyenvalle, A, Seto, JT, Davies, KE and Chamberlain, J (2011). Therapeutic approaches to muscular dystrophy. Hum Mol Genet 20(R1): R69-R78.
30. Vanderplanck, C, Ansseau, E, Charron, S, Stricwant, N, Tassin, A, Laoudj-Chenivesse, D et al. (2011). The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS ONE 6: e26820.
31. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541. (Pubitemid 44050158)
32. Mendell, JR, Rodino-Klapac, LR, Rosales, XQ, Coley, BD, Galloway, G, Lewis, S et al. (2010). Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68: 629-638.
33. Mendell, JR, Rodino-Klapac, LR, Rosales-Quintero, X, Kota, J, Coley, BD, Galloway, G et al. (2009). Limb-girdle muscular dystrophy type 2D gene therapy restores alphasarcoglycan and associated proteins. Ann Neurol 66: 290-297.
34. Chen, YH, Chang, M and Davidson, BL (2009). Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15: 1215-1218.
35. Koerber, JT, Maheshri, N, Kaspar, BK and Schaffer, DV (2006). Construction of diverse adeno-associated viral libraries for directed evolution of enhanced gene delivery vehicles. Nat Protoc 1: 701-706.